| Bioactivity | GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735[1]. |
| CAS | 343322-50-9 |
| Formula | C23H20F3N2NaO4S |
| Molar Mass | 500.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sierra ML, et al. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J Med Chem. 2007;50(4):685-695. [2]. Gateways to clinical trials. July-August 2008 |
GW 590735 sodium
CAS: 343322-50-9 F: C23H20F3N2NaO4S W: 500.47
GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 signif
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.